Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 14.1% on Strong Earnings

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) traded up 14.1% on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $12.29 and last traded at $12.0150. Approximately 510,951 shares traded hands during trading, a decline of 62% from the average session volume of 1,352,691 shares. The stock had previously closed at $10.53.

The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.14. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%.The firm had revenue of $39.66 million during the quarter, compared to analyst estimates of $33.88 million.

Zevra Therapeutics News Summary

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Strong Q2 performance: Zevra reported $39.7 million in second-quarter revenue, up 53% year over year and above analyst expectations. MIPLYFFA generated $30.2 million, while earnings exceeded consensus estimates. The company also reported a strong cash position of $260.2 million, supporting commercialization and regulatory efforts. Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
• Positive Sentiment: Analyst price-target increase: Citizens JMP raised its target for ZVRA from $25 to $28 and reiterated a “market outperform” rating. The revision reinforces the bullish view that MIPLYFFA’s commercial growth and Zevra’s rare-disease pipeline could support substantial long-term upside. Benzinga analyst price-target report
• Positive Sentiment: Regulatory and intellectual-property updates: Zevra said the European Medicines Agency’s CHMP reexamination process for MIPLYFFA is expected to produce an opinion in the fourth quarter. The product’s U.S. Orange Book listing has also been extended to 2041, potentially improving commercial exclusivity and the drug’s long-term revenue outlook. Zevra outlines CHMP reexamination timing
• Neutral Sentiment: Ownership signals are mixed: Several institutional investors increased positions, but others reduced holdings. Recent insider activity showed sales and no reported purchases, which may temper some investor enthusiasm but does not by itself establish a fundamental change.
• Negative Sentiment: Legal overhang: Pomerantz LLP announced an investigation into potential claims on behalf of Zevra investors. The announcement provided few substantive details, but securities investigations can create short-term uncertainty and volatility. Pomerantz investor alert

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Weiss Ratings cut shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Friday, May 22nd. Maxim Group upped their price target on Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. BTIG Research decreased their target price on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating for the company in a report on Monday, July 27th. HC Wainwright restated a “buy” rating and set a $26.00 price target on shares of Zevra Therapeutics in a research note on Tuesday, June 23rd. Finally, Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Thursday. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $27.29.

Institutional Investors Weigh In On Zevra Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. raised its position in shares of Zevra Therapeutics by 15.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after purchasing an additional 550,000 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Zevra Therapeutics by 4.4% in the third quarter. Vanguard Group Inc. now owns 3,083,362 shares of the company’s stock valued at $29,323,000 after acquiring an additional 130,676 shares in the last quarter. Nantahala Capital Management LLC boosted its stake in shares of Zevra Therapeutics by 34.0% during the third quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock valued at $18,753,000 after acquiring an additional 500,000 shares during the last quarter. Rubric Capital Management LP increased its position in Zevra Therapeutics by 60.8% during the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock worth $17,253,000 after purchasing an additional 740,584 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Zevra Therapeutics by 3.9% during the fourth quarter. State Street Corp now owns 1,482,956 shares of the company’s stock worth $13,287,000 after buying an additional 55,665 shares in the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Price Performance

The firm has a market cap of $705.60 million, a price-to-earnings ratio of 5.97 and a beta of 0.91. The business’s 50-day moving average price is $12.31 and its two-hundred day moving average price is $10.55.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.